 | • レポートコード：MRC23Q36227 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、85ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の腫瘍溶解性ウイルス薬物治療市場について調査・分析し、世界の腫瘍溶解性ウイルス薬物治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（フェーズ1、フェーズ2、その他）、用途別セグメント分析（黒色腫、前立腺がん、乳がん、卵巣がん、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Amgen、Oncolytics Biotech、Viralytics、Transgene SA、Oncolys BioPharma、Targovax、PsiOxus Therapeutics、SillaJen Biotherapeutics、Sorrento Therapeutics、Lokon Pharma、Genelux Corporation、Vyriad、TILT Biotherapeutics、Cold Genesysなどが含まれています。 世界の腫瘍溶解性ウイルス薬物治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、腫瘍溶解性ウイルス薬物治療市場規模を推定する際に考慮しました。本レポートは、腫瘍溶解性ウイルス薬物治療の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、腫瘍溶解性ウイルス薬物治療に関するビジネス上の意思決定に役立てることを目的としています。 ・腫瘍溶解性ウイルス薬物治療市場の概要 - 腫瘍溶解性ウイルス薬物治療のタイプ別セグメント - 世界の腫瘍溶解性ウイルス薬物治療市場規模：タイプ別分析（フェーズ1、フェーズ2、その他） - 腫瘍溶解性ウイルス薬物治療の用途別セグメント - 世界の腫瘍溶解性ウイルス薬物治療市場規模：用途別分析（黒色腫、前立腺がん、乳がん、卵巣がん、その他） - 世界の腫瘍溶解性ウイルス薬物治療市場規模予測（2018年-2029年） ・腫瘍溶解性ウイルス薬物治療市場の成長トレンド - 腫瘍溶解性ウイルス薬物治療の地域別市場規模（2018年-2029年） - 腫瘍溶解性ウイルス薬物治療市場ダイナミクス - 腫瘍溶解性ウイルス薬物治療の業界動向 - 腫瘍溶解性ウイルス薬物治療市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：フェーズ1、フェーズ2、その他 - 世界の腫瘍溶解性ウイルス薬物治療のタイプ別市場規模（2018年-2023年） - 世界の腫瘍溶解性ウイルス薬物治療のタイプ別市場規模（2024年-2029年） ・用途別セグメント：黒色腫、前立腺がん、乳がん、卵巣がん、その他 - 世界の腫瘍溶解性ウイルス薬物治療の用途別市場規模（2018年-2023年） - 世界の腫瘍溶解性ウイルス薬物治療の用途別市場規模（2024年-2029年） ・腫瘍溶解性ウイルス薬物治療の地域別市場規模 - 北米の腫瘍溶解性ウイルス薬物治療市場規模（2018年-2029年） - アメリカの腫瘍溶解性ウイルス薬物治療市場規模（2018年-2029年） - ヨーロッパの腫瘍溶解性ウイルス薬物治療市場規模（2018年-2029年） - アジア太平洋の腫瘍溶解性ウイルス薬物治療市場規模（2018年-2029年） - 中国の腫瘍溶解性ウイルス薬物治療市場規模（2018年-2029年） - 日本の腫瘍溶解性ウイルス薬物治療市場規模（2018年-2029年） - 韓国の腫瘍溶解性ウイルス薬物治療市場規模（2018年-2029年） - インドの腫瘍溶解性ウイルス薬物治療市場規模（2018年-2029年） - オーストラリアの腫瘍溶解性ウイルス薬物治療市場規模（2018年-2029年） - 中南米の腫瘍溶解性ウイルス薬物治療市場規模（2018年-2029年） - 中東・アフリカの腫瘍溶解性ウイルス薬物治療市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Amgen、Oncolytics Biotech、Viralytics、Transgene SA、Oncolys BioPharma、Targovax、PsiOxus Therapeutics、SillaJen Biotherapeutics、Sorrento Therapeutics、Lokon Pharma、Genelux Corporation、Vyriad、TILT Biotherapeutics、Cold Genesys ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Oncolytic Virus Drug Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Oncolytic Virus Drug Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Oncolytic Virus Drug Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Oncolytic Virus Drug Treatment in Melanoma is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Oncolytic Virus Drug Treatment include Amgen, Oncolytics Biotech, Viralytics, Transgene SA, Oncolys BioPharma, Targovax, PsiOxus Therapeutics, SillaJen Biotherapeutics and Sorrento Therapeutics, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Oncolytic Virus Drug Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncolytic Virus Drug Treatment.
The Oncolytic Virus Drug Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Oncolytic Virus Drug Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncolytic Virus Drug Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Amgen
Oncolytics Biotech
Viralytics
Transgene SA
Oncolys BioPharma
Targovax
PsiOxus Therapeutics
SillaJen Biotherapeutics
Sorrento Therapeutics
Lokon Pharma
Genelux Corporation
Vyriad
TILT Biotherapeutics
Cold Genesys
Segment by Type
Phase 1
Phase 2
Others
Segment by Application
Melanoma
Prostate Cancer
Breast Cancer
Ovarian Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oncolytic Virus Drug Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oncolytic Virus Drug Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Phase 1
1.2.3 Phase 2
1.2.4 Others
1.3 Market by Application
1.3.1 Global Oncolytic Virus Drug Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Melanoma
1.3.3 Prostate Cancer
1.3.4 Breast Cancer
1.3.5 Ovarian Cancer
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oncolytic Virus Drug Treatment Market Perspective (2018-2029)
2.2 Oncolytic Virus Drug Treatment Growth Trends by Region
2.2.1 Global Oncolytic Virus Drug Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Oncolytic Virus Drug Treatment Historic Market Size by Region (2018-2023)
2.2.3 Oncolytic Virus Drug Treatment Forecasted Market Size by Region (2024-2029)
2.3 Oncolytic Virus Drug Treatment Market Dynamics
2.3.1 Oncolytic Virus Drug Treatment Industry Trends
2.3.2 Oncolytic Virus Drug Treatment Market Drivers
2.3.3 Oncolytic Virus Drug Treatment Market Challenges
2.3.4 Oncolytic Virus Drug Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oncolytic Virus Drug Treatment Players by Revenue
3.1.1 Global Top Oncolytic Virus Drug Treatment Players by Revenue (2018-2023)
3.1.2 Global Oncolytic Virus Drug Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Oncolytic Virus Drug Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Oncolytic Virus Drug Treatment Revenue
3.4 Global Oncolytic Virus Drug Treatment Market Concentration Ratio
3.4.1 Global Oncolytic Virus Drug Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oncolytic Virus Drug Treatment Revenue in 2022
3.5 Oncolytic Virus Drug Treatment Key Players Head office and Area Served
3.6 Key Players Oncolytic Virus Drug Treatment Product Solution and Service
3.7 Date of Enter into Oncolytic Virus Drug Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oncolytic Virus Drug Treatment Breakdown Data by Type
4.1 Global Oncolytic Virus Drug Treatment Historic Market Size by Type (2018-2023)
4.2 Global Oncolytic Virus Drug Treatment Forecasted Market Size by Type (2024-2029)
5 Oncolytic Virus Drug Treatment Breakdown Data by Application
5.1 Global Oncolytic Virus Drug Treatment Historic Market Size by Application (2018-2023)
5.2 Global Oncolytic Virus Drug Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Oncolytic Virus Drug Treatment Market Size (2018-2029)
6.2 North America Oncolytic Virus Drug Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Oncolytic Virus Drug Treatment Market Size by Country (2018-2023)
6.4 North America Oncolytic Virus Drug Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oncolytic Virus Drug Treatment Market Size (2018-2029)
7.2 Europe Oncolytic Virus Drug Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Oncolytic Virus Drug Treatment Market Size by Country (2018-2023)
7.4 Europe Oncolytic Virus Drug Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oncolytic Virus Drug Treatment Market Size (2018-2029)
8.2 Asia-Pacific Oncolytic Virus Drug Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Oncolytic Virus Drug Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Oncolytic Virus Drug Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oncolytic Virus Drug Treatment Market Size (2018-2029)
9.2 Latin America Oncolytic Virus Drug Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Oncolytic Virus Drug Treatment Market Size by Country (2018-2023)
9.4 Latin America Oncolytic Virus Drug Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oncolytic Virus Drug Treatment Market Size (2018-2029)
10.2 Middle East & Africa Oncolytic Virus Drug Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Oncolytic Virus Drug Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Oncolytic Virus Drug Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen
11.1.1 Amgen Company Detail
11.1.2 Amgen Business Overview
11.1.3 Amgen Oncolytic Virus Drug Treatment Introduction
11.1.4 Amgen Revenue in Oncolytic Virus Drug Treatment Business (2018-2023)
11.1.5 Amgen Recent Development
11.2 Oncolytics Biotech
11.2.1 Oncolytics Biotech Company Detail
11.2.2 Oncolytics Biotech Business Overview
11.2.3 Oncolytics Biotech Oncolytic Virus Drug Treatment Introduction
11.2.4 Oncolytics Biotech Revenue in Oncolytic Virus Drug Treatment Business (2018-2023)
11.2.5 Oncolytics Biotech Recent Development
11.3 Viralytics
11.3.1 Viralytics Company Detail
11.3.2 Viralytics Business Overview
11.3.3 Viralytics Oncolytic Virus Drug Treatment Introduction
11.3.4 Viralytics Revenue in Oncolytic Virus Drug Treatment Business (2018-2023)
11.3.5 Viralytics Recent Development
11.4 Transgene SA
11.4.1 Transgene SA Company Detail
11.4.2 Transgene SA Business Overview
11.4.3 Transgene SA Oncolytic Virus Drug Treatment Introduction
11.4.4 Transgene SA Revenue in Oncolytic Virus Drug Treatment Business (2018-2023)
11.4.5 Transgene SA Recent Development
11.5 Oncolys BioPharma
11.5.1 Oncolys BioPharma Company Detail
11.5.2 Oncolys BioPharma Business Overview
11.5.3 Oncolys BioPharma Oncolytic Virus Drug Treatment Introduction
11.5.4 Oncolys BioPharma Revenue in Oncolytic Virus Drug Treatment Business (2018-2023)
11.5.5 Oncolys BioPharma Recent Development
11.6 Targovax
11.6.1 Targovax Company Detail
11.6.2 Targovax Business Overview
11.6.3 Targovax Oncolytic Virus Drug Treatment Introduction
11.6.4 Targovax Revenue in Oncolytic Virus Drug Treatment Business (2018-2023)
11.6.5 Targovax Recent Development
11.7 PsiOxus Therapeutics
11.7.1 PsiOxus Therapeutics Company Detail
11.7.2 PsiOxus Therapeutics Business Overview
11.7.3 PsiOxus Therapeutics Oncolytic Virus Drug Treatment Introduction
11.7.4 PsiOxus Therapeutics Revenue in Oncolytic Virus Drug Treatment Business (2018-2023)
11.7.5 PsiOxus Therapeutics Recent Development
11.8 SillaJen Biotherapeutics
11.8.1 SillaJen Biotherapeutics Company Detail
11.8.2 SillaJen Biotherapeutics Business Overview
11.8.3 SillaJen Biotherapeutics Oncolytic Virus Drug Treatment Introduction
11.8.4 SillaJen Biotherapeutics Revenue in Oncolytic Virus Drug Treatment Business (2018-2023)
11.8.5 SillaJen Biotherapeutics Recent Development
11.9 Sorrento Therapeutics
11.9.1 Sorrento Therapeutics Company Detail
11.9.2 Sorrento Therapeutics Business Overview
11.9.3 Sorrento Therapeutics Oncolytic Virus Drug Treatment Introduction
11.9.4 Sorrento Therapeutics Revenue in Oncolytic Virus Drug Treatment Business (2018-2023)
11.9.5 Sorrento Therapeutics Recent Development
11.10 Lokon Pharma
11.10.1 Lokon Pharma Company Detail
11.10.2 Lokon Pharma Business Overview
11.10.3 Lokon Pharma Oncolytic Virus Drug Treatment Introduction
11.10.4 Lokon Pharma Revenue in Oncolytic Virus Drug Treatment Business (2018-2023)
11.10.5 Lokon Pharma Recent Development
11.11 Genelux Corporation
11.11.1 Genelux Corporation Company Detail
11.11.2 Genelux Corporation Business Overview
11.11.3 Genelux Corporation Oncolytic Virus Drug Treatment Introduction
11.11.4 Genelux Corporation Revenue in Oncolytic Virus Drug Treatment Business (2018-2023)
11.11.5 Genelux Corporation Recent Development
11.12 Vyriad
11.12.1 Vyriad Company Detail
11.12.2 Vyriad Business Overview
11.12.3 Vyriad Oncolytic Virus Drug Treatment Introduction
11.12.4 Vyriad Revenue in Oncolytic Virus Drug Treatment Business (2018-2023)
11.12.5 Vyriad Recent Development
11.13 TILT Biotherapeutics
11.13.1 TILT Biotherapeutics Company Detail
11.13.2 TILT Biotherapeutics Business Overview
11.13.3 TILT Biotherapeutics Oncolytic Virus Drug Treatment Introduction
11.13.4 TILT Biotherapeutics Revenue in Oncolytic Virus Drug Treatment Business (2018-2023)
11.13.5 TILT Biotherapeutics Recent Development
11.14 Cold Genesys
11.14.1 Cold Genesys Company Detail
11.14.2 Cold Genesys Business Overview
11.14.3 Cold Genesys Oncolytic Virus Drug Treatment Introduction
11.14.4 Cold Genesys Revenue in Oncolytic Virus Drug Treatment Business (2018-2023)
11.14.5 Cold Genesys Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details